Related Experiment Video
Updated: Nov 1, 2025
An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
Published on: May 12, 2020
Biological evaluation of mitochondria targeting small molecules as potent anticancer drugs
Shuhua Luo1, Xin Dang1, Juntao Wang1
1Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University (SJTU), No. 800 Dongchuan Rd. Minhang District, Shanghai, 200240, PR China.
Abstract:
Cancer therapy targets specific metabolic pathways or a single gene. This may result in low therapeutic effects due to drug selectivity and drug resistance. Recent studies revealed that the mitochondrial membrane potential and transmembrane permeability of cancerous mitochondria are differed from normal mitochondria. Thus, chemotherapy targeting cancerous mitochondria could be an innovative and competent strategy for cancer therapy. Previously, our work with a novel group of mitochondria targeting small molecules presented promising inhibitory capability toward various cancer cell lines and suppressed adenosine triphosphate (ATP) generation. Therefore, it is critical to understand the anticancer effect and targeting mechanism of these small molecules. This study investigated the inhibitory activity of mitochondria targeting small molecules with human cervical cancer cells - HeLa to further explore their therapeutic potential. HeLa cells were exposed to 10 µM of synthesized compounds and presented elevation in intracellular reactive oxygen species (ROS) level, impaired mitochondrial membrane potential and upregulation of apoptosis as well as necrosis. In vivo, HeLa cell tumor-bearing BALB/c nude mice were treated with mitochondria targeting small molecules for 12 days consecutively. Throughout this chemotherapy study, no deleterious side effects nor the appearance of toxicity was observed. Furthermore, mitochondria targeting small molecules treated groups exhibited significant down-regulation with both tumor volume and tumor weight compared to the Doxorubicin (DOX) treated group. Thus, inhibition of mitochondrial ATP synthesis, activation of intracellular ROS production, down-regulation of mitochondrial membrane potential and upregulation of apoptosis and necrosis rates are the indications of cancer therapy. In this work, we examined the anticancer capability of four mitochondria targeting small molecules in vitro and in vivo, and demonstrated a novel therapeutic approach in cancer therapy with tremendous potential.
Insights
Novel small molecules targeting mitochondria show potent anticancer effects. These compounds effectively reduce tumor growth in vivo with no observed toxicity, offering a promising new strategy for cancer therapy.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Conventional cancer therapies targeting single pathways or genes often face limitations like drug resistance and low efficacy.
- Mitochondria in cancer cells exhibit distinct membrane potential and permeability compared to normal cells, presenting a viable target for novel therapies.
- Previous research demonstrated that novel mitochondria-targeting small molecules can inhibit cancer cell lines and suppress adenosine triphosphate (ATP) generation.
Purpose of the Study:
- To investigate the anticancer activity and mechanism of action of novel mitochondria-targeting small molecules against human cervical cancer (HeLa) cells.
- To evaluate the therapeutic potential of these compounds in an in vivo tumor model.
- To explore the effects on cellular processes including reactive oxygen species (ROS) production, mitochondrial membrane potential, and cell death pathways.
Main Methods:
- In vitro studies involved exposing HeLa cells to 10 µM of synthesized compounds.
- In vivo studies utilized HeLa cell tumor-bearing BALB/c nude mice treated with the compounds for 12 consecutive days.
- Measurements included intracellular ROS levels, mitochondrial membrane potential, apoptosis, necrosis, tumor volume, and tumor weight.
Main Results:
- Mitochondria-targeting small molecules induced increased intracellular ROS, impaired mitochondrial membrane potential, and elevated apoptosis and necrosis in HeLa cells.
- In vivo treatment resulted in significant reduction of tumor volume and weight compared to the Doxorubicin (DOX) control group.
- No deleterious side effects or toxicity were observed during the 12-day in vivo study.
Conclusions:
- Mitochondria-targeting small molecules demonstrate significant anticancer efficacy through inhibition of ATP synthesis, ROS activation, mitochondrial dysfunction, and induction of cell death.
- These compounds represent a novel and potentially effective therapeutic strategy for cancer treatment with a favorable safety profile.
- Targeting mitochondrial dysfunction offers a promising avenue for developing innovative cancer therapies with improved outcomes.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:10Drugs that Destabilize Microtubules
01:15Drugs that Stabilize Microtubules